Navigation Links
China Botanic Pharmaceutical Inc. Announces Withdrawal Of Request For Hearing
Date:6/7/2013

HARBIN, China, June 7, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, announced today that on June 5, 2013, the Company submitted a notice to the NYSE MKT LLC (the "Exchange") of its decision to withdraw its appeal of the Staff's determination to delist the Company's securities from the NYSE MKT. As a result, the Company has been informed that the Company's common stock will be suspended from trading and the Exchange will proceed to file a Form 25 with the Securities and Exchange Commission to delist the Company's common stock from the Exchange.

As previously announced on May 2, 2012, the Company received a notice ("Delisting Notice") from the NYSE MKT LLC ("Exchange") indicating that based on the Company's noncompliance with its compliance plan previously submitted by the Company on February 7, 2013 to regain compliance with Sections 134 and 1101 of the NYSE MKT Company Guide ("Company Guide") by May 1, 2013 (the "Compliance Plan"), the Exchange has made a determination to delist the common stock of the Company from the Exchange. The Delisting Notice indicated that under Sections 1203 and 1009(d) of the Company Guide, the Company has a limited right to appeal the Exchange's determination by requesting an oral hearing or a hearing based on a written submission before the Exchange's Listing Qualifications Panel ("Panel"). On May 9, 2013, the Company submitted a request for a  hearing and paid the applicable hearing fee, and an oral hearing date was set for June 28, 2013. However, based on the progress of its audit, the Company has decided to not appeal by withdrawing its request for hearing. As a result of the Company's decision not to appeal, the Company has been informed that the delisting determination is final and the Exchange will proceed to file an application with the Securities and Exchange Commission to delist the Company's common stock from the Exchange.

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

Company Contact:

China Botanic Pharmaceutical Inc.

Ms. Portia Tan, IR Contact

Tel: 86-451-8260-2162

Email: ir@renhuang.com

 

 


'/>"/>
SOURCE China Botanic Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OrthoTec China 2013 is Coming Up Soon
2. China Biologic Updates the Hong Kong Litigation in respect of the Shares Held by Ms. Siu Ling Chan
3. China & North East Asia Medical Device Market Reports
4. iBio Obtains New IP Protection in China
5. China Nepstar Chain Drugstore Ltd. Reports First Quarter 2013 Financial Results
6. China Nepstar Chain Drugstore Ltd. Announces Appointment of New Director
7. China Biologic Comments on the Proposed Shanghai RAAS Transaction
8. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
9. China Pharmaceutical Market Guidebook Series (4) 2013 Report
10. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
11. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
(Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
(Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is PTSD Awareness Day. Over ... 20% will receive adequate care due to lack of effective treatments, fear of stigma ... all. And left untreated, veterans are at an increased risk for self-destructive behavior, including ...
(Date:6/27/2017)... ... ... Children’s National Health System received top honors in the 2017-18 U.S News & ... of more than 1500 neonatal intensive care units coast to coast. Children’s ... the top performing children’s hospitals in the country. , In addition to achieving ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin ... Specialists, in collaboration with the Fertility Center of California, is pleased to announce ... epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments ...
(Date:6/26/2017)... Mexico (PRWEB) , ... June 26, 2017 , ... ... anorgasmia, and urinary leakage is revolutionizing the way women look and feel about ... tackling the problem of female sexual dysfunction and urinary leakage head on with ...
(Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
Breaking Medicine News(10 mins):